Active Psilocybin Clinical Trials in 2025-2026: What's Enrolling and Where

About This Video

This Psychedelic Alpha overview maps the active psilocybin clinical trial landscape as of early 2026 — what conditions are being studied, which sites are enrolling, what the eligibility requirements look like across major trials, and where the field is likely to generate the most important data in the next two to three years.

The most consequential active trial is COMPASS Pathways' Phase 3 trial for treatment-resistant depression, with COMP360 (synthetic psilocybin). Phase 3 completion data is expected in late 2026 or early 2027, with enrollment at over 100 clinical sites across North America and Europe.

At Johns Hopkins, active enrolling trials include: psilocybin for complicated grief (n=30, Phase 2), psilocybin for tobacco cessation (Phase 2), and a new trial for Alzheimer's disease-associated depression — the first psychedelic trial to focus specifically on this population.

At NYU, active trials include: psilocybin + buprenorphine for opioid use disorder (Phase 2), psilocybin for alcohol use disorder (Phase 2 expansion), and a psilocybin for anorexia nervosa trial (Phase 2, collaboration with UCSD). VA-affiliated trial network has expanded to 12+ medical centers following the April 2026 executive order — veterans with PTSD or TBI can contact their VA for referral.